Vybion Licenses ProCode(TM) Platform.ITHACA Ithaca, city, United States Ithaca (ĭth`əkə), city (1990 pop. 29,541), seat of Tompkins co., S central N.Y., at the southern end of Cayuga Lake, in the Finger Lakes region; settled 1789, inc. as a city 1888. , N.Y. -- Vybion has exclusively licensed a drug development platform from Cornell University. The Platform, called ProCode, can be configured for monoclonal antibody selection, affinity maturation and library generation, for improving solubility and bioactivity bi·o·ac·tiv·i·ty n. The effect of a given agent, such as a vaccine, upon a living organism or on living tissue. of biopharmaceuticals, as well as identification and characterization of protein-protein interactions and discovery of protein drugs. ProCode offers several important advantages that strongly differentiate it from other technologies including dramatic reductions in drug development time, cost, and ease of use. Vybion has licensed patents developed by Drs. George Georgiou and Matthew DeLisa together at the University of Texas at Austin “University of Texas” redirects here. For other system schools, see University of Texas System. The University of Texas at Austin (often referred to as The University of Texas, UT Austin, UT, or Texas and patents developed independently by Dr. DeLisa at Cornell University. These technologies are based on the Twin Arginine arginine (är`jənĭn), organic compound, one of the 20 amino acids commonly found in animal proteins. Only the l-stereoisomer participates in the biosynthesis of proteins. Transport System for which the inventors have an extensive peer reviewed publication portfolio. Vybion uses this technology for in house drug development, partner projects and the Company can sublicense these rights. "We believe this technology, coupled with our NIH "Not invented here." See digispeak. NIH - The United States National Institutes of Health. supported research in collaboration with Dr. DeLisa, will continue to push the frontiers of this technology" said Dr. Lee Henderson, Vybion's CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. . About Vybion, Inc. Vybion is an early stage developer of recombinant proteins for biopharmaceuticals and diagnostics. The Company has developed over 100 proteins with several client products currently in human clinical trials. Vybion has proprietary technologies in the areas of drug discovery, development and gene expression and is experienced in optimization of gene expression, fermentation, upstream and downstream process development and scale up for clinical manufacturing. Vybion technologies are a result of over 10 years of collaborative and internal research. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion